JP2002508361A5 - - Google Patents

Download PDF

Info

Publication number
JP2002508361A5
JP2002508361A5 JP2000539001A JP2000539001A JP2002508361A5 JP 2002508361 A5 JP2002508361 A5 JP 2002508361A5 JP 2000539001 A JP2000539001 A JP 2000539001A JP 2000539001 A JP2000539001 A JP 2000539001A JP 2002508361 A5 JP2002508361 A5 JP 2002508361A5
Authority
JP
Japan
Prior art keywords
compound
effective amount
therapeutically effective
treatment
treatment agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000539001A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002508361A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/023917 external-priority patent/WO1999031074A2/en
Publication of JP2002508361A publication Critical patent/JP2002508361A/ja
Publication of JP2002508361A5 publication Critical patent/JP2002508361A5/ja
Pending legal-status Critical Current

Links

JP2000539001A 1997-12-16 1998-11-10 （（シクロ）アルキル置換）−γ−アミノ酪酸誘導体（＝ＧＡＢＡ類似体）、それらの製造および神経学的疾患の治療における使用 Pending JP2002508361A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6977397P 1997-12-16 1997-12-16
US60/069,773 1997-12-16
US10492498P 1998-10-20 1998-10-20
US60/104,924 1998-10-20
PCT/US1998/023917 WO1999031074A2 (en) 1997-12-16 1998-11-10 ((cyclo)alkyl substituted)-.gamma.-aminobutyric acid derivatives (=gaba analogues), their preparation and their use in the treatment of neurological disorders

Publications (2)

Publication Number Publication Date
JP2002508361A JP2002508361A (ja) 2002-03-19
JP2002508361A5 true JP2002508361A5 (enExample) 2009-09-10

Family

ID=26750408

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000539001A Pending JP2002508361A (ja) 1997-12-16 1998-11-10 （（シクロ）アルキル置換）−γ−アミノ酪酸誘導体（＝ＧＡＢＡ類似体）、それらの製造および神経学的疾患の治療における使用

Country Status (23)

Country Link
US (2) US6521650B1 (enExample)
EP (2) EP1400526A3 (enExample)
JP (1) JP2002508361A (enExample)
KR (1) KR20010033154A (enExample)
CN (1) CN1210268C (enExample)
AT (1) ATE260904T1 (enExample)
AU (1) AU759619B2 (enExample)
BR (1) BR9813656A (enExample)
CA (1) CA2304965C (enExample)
CU (1) CU23028A3 (enExample)
DE (1) DE69822214T2 (enExample)
DK (1) DK1045839T3 (enExample)
ES (1) ES2216338T3 (enExample)
HU (1) HUP0100472A3 (enExample)
IL (1) IL135314A0 (enExample)
IS (1) IS5436A (enExample)
NO (2) NO317251B1 (enExample)
NZ (1) NZ503981A (enExample)
PL (1) PL348305A1 (enExample)
PT (1) PT1045839E (enExample)
SI (1) SI1045839T1 (enExample)
TR (1) TR200001794T2 (enExample)
WO (1) WO1999031074A2 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
GB2365425A (en) * 2000-08-01 2002-02-20 Parke Davis & Co Ltd Alkyl amino acid derivatives useful as pharmaceutical agents
EP1343805A4 (en) 2000-10-06 2005-07-20 Xenoport Inc COMPOUNDS DERIVED FROM GALLENIC ACIDS FOR THE PROVISION OF CONTINUING SYSTEMIC CONCENTRATIONS OF MEDICINAL PRODUCTS AFTER ORAL ADMINISTRATION
US6900192B2 (en) 2000-10-06 2005-05-31 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
US6620829B2 (en) 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
GB2368579A (en) * 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
CN101434572B (zh) * 2001-06-11 2013-03-13 什诺波特有限公司 Gaba类似物的前药、及其组合物和应用
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
PT1404324E (pt) 2001-06-11 2008-03-05 Xenoport Inc Formas de dosagem administradas oralmente de pró-fármacos análogas de gaba tendo toxicidade reduzida
AU2002345638A1 (en) 2001-06-11 2002-12-23 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CA2474000A1 (en) * 2002-01-31 2003-08-07 Warner-Lambert Company Llc Alpha 2 delta ligands to treat tinnitus
US7026351B2 (en) 2002-03-20 2006-04-11 Xenoport, Inc. Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof
WO2004002462A2 (en) * 2002-06-27 2004-01-08 Warner-Lambert Company Llc Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder
US7060727B2 (en) 2002-12-11 2006-06-13 Xenoport, Inc. Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
NZ567457A (en) 2002-12-13 2009-08-28 Warner Lambert Co Alpha-2-delta ligand to treat lower urinary tract symptoms
WO2004078734A1 (en) * 2003-03-07 2004-09-16 Warner-Lambert Company Llc TETRAZOLE AND OXADIAZOLONE SUBSTITUTED β-AMINO ACID DERIVATIVES
WO2005013888A2 (en) * 2003-05-14 2005-02-17 Cytokinetics, Inc. Compounds, compositions and methods
EP1670451A4 (en) 2003-09-11 2009-10-21 Xenoport Inc TREATMENT AND / OR PREVENTION OF URINARY INCONTINENCE AND PROMOTERS OF GABA ANALOGS
MXPA06002789A (es) 2003-09-12 2006-06-14 Pfizer Combinaciones que comprenden ligandos alfa-2-delta.
RU2377234C2 (ru) * 2003-09-17 2009-12-27 Ксенопорт, Инк. Лечение или предупреждение синдрома беспокойных ног с использованием пролекарств аналогов гамк
WO2005027850A2 (en) * 2003-09-17 2005-03-31 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
KR101096480B1 (ko) 2003-10-14 2011-12-20 제노포트 인코포레이티드 감마-아미노부티르산 유사체의 결정질 형태
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
US20050209319A1 (en) * 2004-03-18 2005-09-22 Xenoport, Inc. Treatment of local pain
WO2006012603A2 (en) * 2004-07-22 2006-02-02 Nps Pharmaceuticals, Inc. Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases
US7449486B2 (en) 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
US8795725B2 (en) 2004-11-04 2014-08-05 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
UA95907C2 (en) * 2005-05-02 2011-09-26 Эррей Биофарма Инк. Mitotic kinesin inhibitors and methods of use thereof
WO2007035789A1 (en) * 2005-09-19 2007-03-29 Teva Pharmaceutical Industries Ltd. Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the new synthesis of (s)-pregabalin
WO2008042928A2 (en) * 2006-10-03 2008-04-10 Array Biopharma, Inc. Oxadiazole and thiadiazole derivatives as mitotic kinesin inhibitors and methods of use thereof
CN102058885B (zh) 2006-12-22 2013-04-10 瑞蔻达蒂爱尔兰有限公司 采用α2δ配体和NSAID的下泌尿道疾病的联合治疗
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
US7872046B2 (en) 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
JP5563483B2 (ja) 2008-01-25 2014-07-30 ゼノポート，インコーポレイティド アシロキシアルキルカルバメートプロドラッグの合成に使用されるアシロキシアルキルチオカーボネートの鏡像異性的な分解
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
US20100087525A1 (en) * 2008-06-23 2010-04-08 Lilach Hedvati Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester
ES2589915T3 (es) 2008-10-08 2016-11-17 Xgene Pharmaceutical Inc Conjugados de GABA y métodos de utilización de los mismos
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
AU2014209028C1 (en) 2013-01-28 2019-08-29 Hector L. Lopez Methods of improving tolerability, pharmacodynamics, and efficacy of b-alanine and use therefor
AU2014364644A1 (en) 2013-12-17 2016-06-23 Laboratorios Del Dr. Esteve, S.A. Gabapentinoids and Sigma receptor ligands combinations
AU2014364647A1 (en) 2013-12-17 2016-06-23 Laboratorios Del Dr. Esteve, S.A. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Sigma receptor ligands combinations
CN105481801B (zh) * 2015-12-11 2021-08-13 广东莱佛士制药技术有限公司 一种普瑞巴林手性中间体的制备方法
CN108358799B (zh) * 2018-04-24 2020-11-10 贵州师范大学 一种普瑞巴林的制备方法
CN117986143A (zh) * 2022-11-03 2024-05-07 中科中山药物创新研究院 含有多环结构的γ-氨基丁酸衍生物及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2465803A (en) * 1944-02-12 1949-03-29 Ici Ltd Beta-nitroalkane sulfonic acids
CH325458A (de) * 1953-03-14 1957-11-15 Ruhrchemie Ag Verfahren zur Herstellung von Sultamen
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US4456757A (en) * 1981-03-20 1984-06-26 Asahi Kasei Kogyo Kabushiki Kaisha Isoquinolinesulfonyl derivatives and process for the preparation thereof
JPS6023360A (ja) * 1983-07-18 1985-02-05 Mitsui Toatsu Chem Inc アミノアルキルスルホン酸類の製造法
SE455259B (sv) * 1984-01-30 1988-07-04 Kenogard Ab Anvendning av vissa aminoalkanfosfonsyror for bekempning av svampsjukdomar hos vexter
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
AU9137091A (en) * 1990-11-27 1992-06-25 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
FR2674522B1 (fr) * 1991-03-26 1993-07-16 Lipha Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant.
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
WO1996005201A1 (en) * 1994-08-10 1996-02-22 British Biotech Pharmaceuticals Limited Imidazopyridine derivatives as dual histamine (h1) and platelet activating factor (paf) antagonists
AU733896B2 (en) * 1996-10-23 2001-05-31 Warner-Lambert Company Substituted gamma aminobutyric acids as pharmaceutical agents

Similar Documents

Publication Publication Date Title
JP2002508361A5 (enExample)
JP2021063088A5 (enExample)
JP2003531118A5 (enExample)
JP2005500357A5 (enExample)
JP2002527474A5 (ja) 躁病および双極性障害の治療のための医薬
JP2002518502A5 (enExample)
JP2002533472A5 (enExample)
JP2007503202A5 (enExample)
JP2001525359A5 (enExample)
JP2003503454A5 (enExample)
RU2005108133A (ru) Дипептиднитрильные ингибиторы катепсина к
JP2007514005A5 (enExample)
JP2002508352A5 (ja) ４(３)置換−４(３)−アミノメチル−（チオ）ピラン又はピペリジン誘導体（＝ガバペンチン類似体）
JP2004526788A5 (enExample)
JP2006507220A5 (enExample)
JPH1133743A5 (enExample)
JP2002522501A5 (enExample)
JP2003502367A5 (enExample)
JP2003519228A5 (enExample)
JP2002528502A5 (enExample)
JP2002542248A5 (enExample)
JP2003525207A5 (enExample)
JP2002506864A5 (enExample)
JP2002525330A5 (enExample)
JP2003520208A5 (enExample)